Stay updated on Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page.

Latest updates to the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an updated version number from v2.16.0 to v2.16.1.SummaryDifference1%
- Check21 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check57 days agoChange DetectedThe page has been updated to include information about a study on Metastatic Breast Cancer, specifically referencing a new revision version. However, significant details about the trial, including its design and inclusion/exclusion criteria, have been removed.SummaryDifference46%
- Check64 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page.